The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

• Main Authors: Pillozzi, Serena, D'Amico, Massimo, Bartoli, Gianluca, Gasparoli, Luca, Petroni, Giulia, Crociani, Olivia, Marzo, Tiziano, Guerriero, Angela, Messori, Luigi, Severi, Mirko, Udisti, Roberto, Wulff, Heike, Chandy, Kanianthara George, Becchetti, Andrea, Arcangeli, Annarosa
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2020
• Subjects: Science::Medicine; Riluzole; SKA-31
• Online Access: https://hdl.handle.net/10356/138851
• Institution: Nanyang Technological University

Background: Platinum-based drugs such as Cisplatin are commonly employed for cancer treatment. Despite an initial therapeutic response, Cisplatin treatment often results in the development of chemoresistance. To identify novel approaches to overcome Cisplatin resistance, we tested Cisplatin in combi...